GenMark Diagnostics (GNMK) PT Raised to $9 at Cowen After Revenue and Profits Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts GNMK Hot Sheet
Rating Summary:
2 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Cowen analyst Doug Schenkel raised the price target on GenMark Diagnostics (NASDAQ: GNMK) to $9.00 (from $8.00) after the company pre-announced a ~$12MM revenue beat and increased full year guidance. Additionally, gross margin of 40% was ~550bp above expectations.
The analyst maintained an Outperform rating, stating "We expect upside vs. revised guidance, with particular strength likely later this year as GNMK incorporates COVID-19 into its full respiratory panel. The near- and long-term risk/reward appears attractive. PT to $9 (DCF; 4.5x 2020 sales)".
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Insulet Corporation (PODD) PT Raised to $163 at TD Cowen
- Datadog (DDOG) PT Lowered to $230 at Jefferies
- Matador (MTDR) PT Raised to $66 at Truist Securities
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
